Research ArticleCancer

MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma

See allHide authors and affiliations

Science Translational Medicine  04 Jul 2018:
Vol. 10, Issue 448, eaan4470
DOI: 10.1126/scitranslmed.aan4470

Article Information

vol. 10 no. 448

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication September 26, 2017
  • Accepted for publication June 6, 2018

Author Information

  1. Marielle E. Yohe1,2,*,,
  2. Berkley E. Gryder1,,
  3. Jack F. Shern2,
  4. Young K. Song1,
  5. Hsien-Chao Chou1,
  6. Sivasish Sindiri1,
  7. Arnulfo Mendoza2,
  8. Rajesh Patidar1,
  9. Xiaohu Zhang3,
  10. Rajarashi Guha3,,
  11. Donna Butcher4,
  12. Kristine A. Isanogle5,
  13. Christina M. Robinson5,
  14. Xiaoling Luo6,
  15. Jin-Qiu Chen6,
  16. Ashley Walton1,
  17. Parirokh Awasthi5,
  18. Elijah F. Edmondson4,
  19. Simone Difilippantonio5,
  20. Jun S. Wei1,
  21. Keji Zhao7,
  22. Marc Ferrer3,
  23. Craig J. Thomas3 and
  24. Javed Khan1,*
  1. 1Oncogenomics Section, Genetics Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD 20892, USA.
  2. 2Pediatric Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
  3. 3Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Bethesda, MD 20892, USA.
  4. 4Pathology/Histotechnology Laboratory, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, NIH, Frederick, MD 21702, USA.
  5. 5Laboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, NIH, Frederick, MD 21701, USA.
  6. 6Collaborative Protein Technology Resource, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
  7. 7Systems Biology Center, National Heart Lung and Blood Institute, NIH, Bethesda, MD 20892, USA.
  1. *Corresponding author. Email: yoheme{at}mail.nih.gov (M.E.Y.); khanjav{at}mail.nih.gov (J.K.)
    • These authors contributed equally to this work.

    • Present address: Vertex Pharmaceuticals, Boston, MA 02210, USA.

    Altmetric

    Article usage

    Article usage: July 2018 to July 2019

    AbstractFullPdf
    Jul 20185278269451
    Aug 20181718291
    Sep 20181636554
    Oct 20181234957
    Nov 20181355750
    Dec 20181523630
    Jan 20191206045
    Feb 20191494943
    Mar 20192264037
    Apr 20192083532
    May 20191993423
    Jun 20191122427
    Jul 2019127238

    Navigate This Article